BTIG analyst Mark Massaro lowered the firm's price target on Personalis to $11 from $13 and keeps a Buy rating on the shares. The company delivered a slight Q1 revenue beat and also beat the firm's estimate on its NeXT Personal MRD test, though BTIG is reducing its price target to reflect the recent multiple compression in the specialty lab space, the analyst tells investors in a research note.
